Cyclophosphamide is an important therapy for patients with severe rheumatic diseases; it is, however, responsible for gonadal toxicity. There are a number of interventions aimed at reducing this toxicity, including estrogen-containing oral contraceptives, hormone agonists and antagonists of gonadal receptors in females, and testosterone therapy and storage of gametes for male patients. These strategies are outlined in this article.
